Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Grail (Biotechnology)

Grail (Biotechnology)
2015 FOUNDED
PRIVATE STATUS
Series C LATEST DEAL TYPE
$300M LATEST DEAL AMOUNT
35 INVESTORS
Description

Developer of a pan-cancer screening test designed to detect cancer early. The company's pan-cancer screening test measures circulating nucleic acids in blood using high-intensity sequencing, population-scale clinical trials, enabling doctors to develop blood tests for early-stage cancer detection.

Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Primary Office
  • 1525 O'Brien Drive
  • Menlo Park, CA 94025
  • United States

+1 (650) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Grail (Biotechnology)’s full profile, request a free trial.

Grail (Biotechnology) Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series C) 21-May-2018 $300M 00.000 00.00 Completed Generating Revenue
2. Early Stage VC (Series B) 22-Nov-2017 00.000 00.000 00.000 Completed Startup
1. Early Stage VC (Series A) 08-Jan-2016 $100M $100M 00000 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Grail (Biotechnology) Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series C 00,000,000 00.000000 00.00 00.00 00 00.00 0.000
Series B 000,000,000 00.000000 00.00 00.00 00 00.00 00.000
Series A 85,000,000 $0.001000 $1 $1 1x $1 12.62%
To view this company’s complete Cap Table, request access »

Grail (Biotechnology) Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 31-May-2017 000000000000000000 Biotechnology 0000000 00000
To view this company’s complete investment and acquisition history, request access »

Grail (Biotechnology) Investors (35)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
6 Dimensions Capital Venture Capital Minority 000 0000 000000 0
Ally Bridge Group Venture Capital Minority 000 0000 000000 0
Blue Pool Capital Family Office Minority 000 0000 000000 0
China Merchants Securities Asset Manager Minority 000 0000 000000 0
Community Reinvestment Fund Impact Investing Minority 000 0000 000000 0
You’re viewing 5 of 35 investors. Get the full list »

Grail (Biotechnology) Executive Team (7)

Name Title Board
Seat
Contact
Info
Jennifer Cook Chief Executive Officer & Board Member
Kenneth Drazan MD President
Aaron Freidin Corporate Controller
Richard Rava Ph.D Chief Product Officer
Jeffrey Huber Vice Chairman & Co-Founder

2 Former Executives

You’re viewing 5 of 7 executives. Get the full list »

Grail (Biotechnology) Board Members (11)

Name Representing Role Since Contact
Info
Brook Byers Ph.D Self Board Member 000 0000
Catherine Friedman Self Board Member 000 0000
Jeffrey Huber Grail (Biotechnology) Vice Chairman & Co-Founder 000 0000
Jennifer Cook Grail (Biotechnology) Chief Executive Officer & Board Member 000 0000
Kaye Foster Grail (Biotechnology) Board of Director 000 0000

1 Former Board Member

You’re viewing 5 of 11 board members. Get the full list »